Novel nucleic acid sequences encoding G-protein coupled receptors
    2.
    发明申请
    Novel nucleic acid sequences encoding G-protein coupled receptors 审中-公开
    编码G蛋白偶联受体的新型核酸序列

    公开(公告)号:US20060275866A1

    公开(公告)日:2006-12-07

    申请号:US11268745

    申请日:2005-11-07

    CPC分类号: C07K14/705

    摘要: The invention provides isolated nucleic acids molecules, designated 2871, 14926, 44576, 23992, 1983, 52881, 2398, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor family members that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 proteins, fusion proteins, antigenic peptides and anti-2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供分离的核酸分子,命名为2871,14926,4457,239992,1983,52881,2988和52872核酸分子,其编码编码新多肽的新型G蛋白偶联受体家族成员。 本发明还提供反义核酸分子,含有2871,14926,4576,23992,1983,52881,2398或52872核酸分子的重组表达载体,已经引入了表达载体的宿主细胞,以及非人转基因动物,其中 已经引入或破坏了2871,14926,44576,23992,1983,52881,2398或52872基因。 本发明还进一步提供了分离的2871,14926,4457,239992,1983,52881,2398或52872蛋白质,融合蛋白,抗原肽和抗-2871,14926,4457,23992,1983,52881,29898或52872抗体。 还提供了利用本发明组合物的诊断方法。

    Human protein kinase, phosphatase, and protease family members and uses thereof
    6.
    发明授权
    Human protein kinase, phosphatase, and protease family members and uses thereof 失效
    人蛋白激酶,磷酸酶和蛋白酶家族成员及其用途

    公开(公告)号:US07070947B2

    公开(公告)日:2006-07-04

    申请号:US10170789

    申请日:2002-06-13

    摘要: The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted. The invention still further provides isolated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic peptides and anti-2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供编码新的人蛋白激酶家族成员,丝氨酸/苏氨酸蛋白激酶家族的分离的核酸分子,命名为2504,15977,14760,53070,15985,5042,56583,21953,m32404,14089和23436核酸分子 成员,己糖激酶家族成员,丝氨酸/苏氨酸磷酸酶家族成员,脯氨酰寡肽酶家族成员,胰蛋白酶家族成员,胰蛋白酶丝氨酸蛋白酶家族成员和泛素蛋白酶家族成员。 本发明还提供了反义核酸分子,含有2504,15977,14760,53070,15985,5042,26583,21953,m32404,14089或23436核酸分子的重组表达载体,已经引入表达载体的宿主细胞, 和非人类转基因动物,其中引入或破坏了2504,15977,14760,53070,15985,550365,26583,21953,m32404,14089或23436基因。 本发明还进一步提供分离的2504,15977,14760,53070,15985,5038,26583,21953,m32404,14089或23436蛋白,融合蛋白,抗原肽和抗2504,15977,14760,53070,15985,50365, 26583,21953,m32404,14089或23436抗体。 还提供了利用本发明组合物的诊断方法。

    Methods and compositions for treating AIDS and HIV-related disorders using 1414, 1481,1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 or 2045 molecules
    8.
    发明申请
    Methods and compositions for treating AIDS and HIV-related disorders using 1414, 1481,1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 or 2045 molecules 审中-公开
    使用1414,1481,1553,3402,1720,1683,1552,1682,1675,122825,9952,5816,10002,1611,1371,14324,126,270,312,39, 167,326,18926,6747,1793,1784或2045分子

    公开(公告)号:US20070031882A1

    公开(公告)日:2007-02-08

    申请号:US11545891

    申请日:2006-10-11

    IPC分类号: C12Q1/68 C12P21/06

    CPC分类号: C12Q1/703

    摘要: The present invention relates to methods for the diagnosis and treatment of AIDS or an HIV-related disorder or disorders. Specifically, the present invention identifies the differential expression of 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784 and 2045 genes in tissues relating to AIDS or an HIV-related disorder, relative to their expression in normal, or non-AIDS or HIV-related disease states, and/or in response to manipulations relevant to AIDS or an HIV-related disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various HIV-related disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating AIDS or an HIV-related disorder or disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of AIDS or an HIV-related disorder.

    摘要翻译: 本发明涉及用于诊断和治疗AIDS或HIV相关疾病或病症的方法。 具体地说,本发明鉴定1414,1481,1553,34021,1720,1683,1552,1682,1675,122825,9952,516,10002,1611,1371,14324,126,270,312, 相对于其在正常或非艾滋病或HIV相关疾病状态中的表达,和/或响应于相关操作相关的与艾滋病或HIV相关疾病有关的组织中的326,389,267,47,47和1784和2045个基因 艾滋病或艾滋病毒相关疾病。 本发明描述了用于各种HIV相关疾病的诊断评价和预后的方法,以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节艾滋病或HIV相关疾病或病症的化合物的方法。 本发明还提供了用于鉴定和治疗性使用化合物作为AIDS或HIV相关病症治疗的方法。

    Selectin ligand interactor cytoplasmic (SLIC-1), a P-selectin glycoprotein ligand (PSGL-1) binding protein
    10.
    发明授权
    Selectin ligand interactor cytoplasmic (SLIC-1), a P-selectin glycoprotein ligand (PSGL-1) binding protein 失效
    选择素配体相互作用细胞质(SLIC-1),P-选择素糖蛋白配体(PSGL-1)结合蛋白

    公开(公告)号:US07405272B2

    公开(公告)日:2008-07-29

    申请号:US10961070

    申请日:2004-10-12

    IPC分类号: C07K14/705

    摘要: The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供编码新型P-选择素糖蛋白配体(PSGL-1)结合分子的分离的核酸分子,命名为SLIC-1核酸分子。 本发明还提供了反义核酸分子,含有SLIC-1核酸分子的重组表达载体,其中引入了表达载体的宿主细胞,以及SLIC-1基因导入或破坏的非人类转基因动物。 本发明还进一步提供了分离的SLIC-1蛋白,融合蛋白,抗原肽和抗SLIC-1抗体。 还提供了利用本发明组合物的诊断方法。